Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
复制标题
DOI：
10.1245/s10434-011-2108-2
复制
发表时间：
2012-05-01
影响因子：
3.7
通讯作者：
Pusztai, Lajos
中科院分区：
文献类型：
--
作者：
Kaufmann, Manfred;von Minckwitz, Gunter;Pusztai, Lajos
新辅助系统疗法(NST)在乳腺癌治疗中的应用不断增加，特别是在新治疗方案的试验中。在1980年的S，NST被证明可以显著提高保乳手术率，并首次被典型地用于不能手术的局部晚期或炎症性乳腺癌患者。自那以后，研究人员也使用NST作为体内化疗敏感性的测试，通过评估病理完全反应。今天，通过使用病理反应和其他生物标记物作为中间终点，使用NST的新方案和疗法的试验结果旨在先于和预测更大规模佐剂试验的结果。2003年，一个由不同乳腺癌临床研究小组的代表组成的小组首次在Biedenkopf召开会议，就NST的使用提出建议。在随后于2004年和2006年举行的两次会议上更新了所取得的共识。最近一次关于使用NST建议的会议是在2010年举行的，构成了本报告的基础。
The use of neoadjuvant systemic therapy (NST) for the treatment of primary breast cancer has constantly increased, especially in trials of new therapeutic regimens. In the 1980 s, NST was shown to substantially improve breast-conserving surgery rates and was first typically used for patients with inoperable locally advanced or inflammatory breast cancer. Investigators have since also used NST as an in vivo test for chemosensitivity by assessing pathologic complete response. Today, by using pathologic response and other biomarkers as intermediate end points, results from trials of new regimens and therapies that use NST are aimed to precede and anticipate the results from larger adjuvant trials. In 2003, a panel of representatives from various breast cancer clinical research groups was first convened in Biedenkopf to formulate recommendations on the use of NST. The obtained consensus was updated in two subsequent meetings in 2004 and 2006. The most recent conference on recommendations on the use of NST took place in 2010 and forms the basis of this report.